Search Result

Results for "

Cyclin A/B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (73) Cyclin G-associated Kinase (GAK) (1) Akt (1) Androgen Receptor (2) APC (2) Apoptosis (28) Aryl Hydrocarbon Receptor (1) Atg8/LC3 (1) ATTECs (1) Aurora Kinase (2) Autophagy (11) Bcl-2 Family (1) c-Myc (1) Casein Kinase (2) Caspase (5) CFTR (1) Checkpoint Kinase (Chk) (1) DNA/RNA Synthesis (3) Drug Isomer (1) Epigenetic Reader Domain (2) ERK (2) FGFR (1) GSK-3 (18) HSP (1) Isotope-Labeled Compounds (1) JAK (2) JNK (2) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) MDM-2/p53 (5) MEK (2) MicroRNA (1) Microtubule/Tubulin (4) Mitosis (1) Molecular Glues (5) mTOR (1) p38 MAPK (1) Parasite (3) PKC (1) Polo-like Kinase (PLK) (1) PROTACs (2) PSMA (2) Reactive Oxygen Species (ROS) (2) Reference Standards (6) STAT (3) TOPK (2) Topoisomerase (1) VEGFR (2) Wee1 (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (89) Infection (3) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (5)

By Targets:

CDK (73)

Cyclin G-associated Kinase (GAK) (1)

Akt (1)

Androgen Receptor (2)

APC (2)

Apoptosis (28)

Aryl Hydrocarbon Receptor (1)

Atg8/LC3 (1)

ATTECs (1)

Aurora Kinase (2)

Autophagy (11)

Bcl-2 Family (1)

c-Myc (1)

Casein Kinase (2)

Caspase (5)

CFTR (1)

Checkpoint Kinase (Chk) (1)

DNA/RNA Synthesis (3)

Drug Isomer (1)

Epigenetic Reader Domain (2)

ERK (2)

FGFR (1)

GSK-3 (18)

HSP (1)

Isotope-Labeled Compounds (1)

JAK (2)

JNK (2)

Ligands for Target Protein for PROTAC (1)

Lipoxygenase (1)

MDM-2/p53 (5)

MEK (2)

MicroRNA (1)

Microtubule/Tubulin (4)

Mitosis (1)

Molecular Glues (5)

mTOR (1)

p38 MAPK (1)

Parasite (3)

PKC (1)

Polo-like Kinase (PLK) (1)

PROTACs (2)

PSMA (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (6)

STAT (3)

TOPK (2)

Topoisomerase (1)

VEGFR (2)

Wee1 (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (89)

Infection (3)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Cyclin G-associated Kinase (GAK) CDK CDKL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18299

Purvalanol B 1 Publications Verification NG 95	CDK Parasite	Infection Cancer
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .

HY-18299A

Purvalanol A 2 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-12529

Ro-3306 50+ Cited Publications	CDK Apoptosis	Cancer
Ro-3306 is a potent and selective inhibitor of CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

HY-10014

R547 2 Publications Verification	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-175729

Cyclin A/B RxL-IN-1	CDK	Cancer
Cyclin A/B RxL-IN-1 is a inhibitor targeting the Cyclin A/B RxL interaction at the hydrophobic patch (HP). Cyclin A/B RxL-IN-1 inhibits Cyclin A with an IC₅₀ of 0.12 μM. Cyclin A/B RxL-IN-1 demonstrates antitumor efficacy in mouse cell line-derived xenograft (CDX) models. CDK-IN-19 can be used for the study of E2F-driven cancers such as small-cell lung cancer (SCLC) .

HY-111260

R547 mesylate	CDK GSK-3 Apoptosis	Cancer
R547 mesylate is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent CDK inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-15612

CDK4-IN-1	CDK	Cancer
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-18299AR

Purvalanol A (Standard)	CDK Autophagy Apoptosis	Cancer
Purvalanol A (Standard) is the analytical standard of Purvalanol A. This product is intended for research and analytical applications. Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.

HY-18299B

(S)-Purvalanol B (S)-NG 95	Drug Isomer	Others
(S)-Purvalanol B is the S enantiomer of Purvalanol B. Purvalanol B is a cyclin-dependent kinase inhibitor.

HY-144971

dCeMM2	Molecular Glues CDK	Cancer
dCeMM2 (Compound 2) is a molecular glue-type degrader that targets cyclin K. dCeMM2 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .

HY-112394

2-Cyanoethylalsterpaullone	GSK-3 CDK	Cancer
2-Cyanoethylalsterpaullone (compound 7) is an Alsterpaullone (HY-108359) derivative, which exhibits potent and selective inhibitory activities against CDK1/Cyclin B and GSK-3β (GSK-3β: IC₅₀=0.8 nM; CDK1/Cyclin B: IC₅₀=0.23 nM) .

HY-144977

dCeMM4	Molecular Glues CDK	Cancer
dCeMM4 (Compound 5) is a molecular glue degrader. dCeMM4 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-144976

dCeMM3	Molecular Glues CDK	Cancer
dCeMM3 (Compound 3) is a molecular glue degrader. dCeMM3 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a *CRL4B* ligase complex .

HY-117535

CDK2-IN-4 3 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-136841

SLM6	CDK	Cancer
SLM6 is a sangivamycin-like molecule. SLM6 is a CDK9 inhibitor. SLM6 inhibits CDK9/cyclin K and CDK9/cyclin T1 kinase activity with IC₅₀s of 280 nM and 133 nM, respectively. SLM6 also inhibits CDK1/cyclin B and CDK2/ cyclin A with IC₅₀s of less than 300 nM. SLM6 induces apoptosis in multiple myeloma (MM) cells .

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-103221

MeBIO	Aryl Hydrocarbon Receptor GSK-3 CDK	Others
MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC₅₀ of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively .

HY-156296

*CDK9-Cyclin* T1 PPI-IN-1**	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .

HY-119715

AG-012986	CDK Apoptosis	Cancer
AG-012986 is a multitargeted CDK inhibitor. AG-012986 is active against CDK1/2/4/6/5/9, with K_is of 9.2 nM (CDK4/cyclin), 94 nM (CDK2/cyclin A), and 44 nM (CDK1/cyclin B), IC₅₀s of 4 nM (CDK9/cyclin T) and 22 nM (CDK5/p35). AG-012986 has antiproliferative activities against cancer cells. AG-012986 induces cell cycle arrest, and apoptosis .

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM) .

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, **cyclin B1-CDK1*, cyclin* E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, **cyclin B1-CDK1*, cyclin* E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-18340

(R)-CR8 CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-12302

Kenpaullone 5+ Cited Publications 9-Bromopaullone; NSC-664704	CDK GSK-3	Cancer
Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC₅₀s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC₅₀s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.

HY-10424R

Milciclib (Standard) PHA-848125 (Standard)	Reference Standards CDK Autophagy	Cancer
Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-18340A

(R)-CR8 trihydrochloride CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .

HY-W011428

Olomoucine	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 μM), CDK/p35 kinase (IC₅₀=3 μM) and ERK1/p44 MAP kinase (IC₅₀=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-W011428R

Olomoucine (Standard)	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively .

HY-114903

(E/Z)-BIO-acetoxime GSK-3 Inhibitor X	GSK-3 CDK	Neurological Disease Metabolic Disease Cancer
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC₅₀=2.4, 4.3, 63 μM) .

HY-118976

CGP-74514 hydrochloride CGP-74514A	CDK Apoptosis	Cancer
CGP-74514 hydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC₅₀: 25 nM). CGP-74514 hydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G₂/M phase and induces tumor cell apoptosis. CGP-74514 hydrochloride is promising for research of bladder cancer .

HY-N0417

Cucurbitacin E 5+ Cited Publications α-Elaterin; α-Elaterine	CDK Autophagy	Cancer
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-149261

H1k	Autophagy CDK	Cancer
H1k, a Eudistomin Y derivative, is a lysosome-targeted antiproliferation agent. H1k increases the autophagy signal and downregulate the expression of cyclin-dependent kinase (CDK1) and cyclin B1. H1k can be used in research of cancer .

HY-110359

CGP-74514 dihydrochloride	CDK Apoptosis	Cancer
CGP-74514 dihydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC₅₀=25 nM). CGP-74514 dihydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G₂/M phase and induces tumor cell apoptosis. CGP-74514 dihydrochloride is promising for research of bladder cancer .

HY-11012

TDZD-8 10+ Cited Publications GSK-3β Inhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of GSK-3β, with an IC₅₀ of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-115565

CGP-74514	CDK Apoptosis	Cancer
CGP-74514 (Compound 13) is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC₅₀=25 nM). CGP-74514 inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G₂/M phase and induces tumor cell apoptosis. CGP-74514 is promising for research of bladder cancer .

HY-112336

Aloisine RP106	CDK GSK-3	Neurological Disease
Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, Cdk5/p25, and GSK3 with IC₅₀s of 0.70µM, 1.5µM, 0.92 µM, respectively .

HY-E70653

CDK1/CycB1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycB1 Recombinant Human Active Protein Kinase is an ortholog of CDK1. CDK1/cyclin B1 complexes initiates mitotic entry by phosphorylating a multitude of proteins to condense chromosomes, disrupt the nuclear envelope, and enable microtubules polymerization to attach and to segregate the chromosomes .

HY-118902

Aloisine B	CDK	Others
Aloisine B (compound 9) is a cyclin-dependent kinase (CDK) inhibitor. Aloisine B inhibits cell proliferation by arresting cells in both G1 and G2 via competing with ATP-binding pocket .

HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621	CDK GSK-3 VEGFR FGFR	Cancer
3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC₅₀s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC₅₀=0.041 μM) and modest potency against CDK4, VEGF-R2, and FGF-R2 (IC₅₀=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer .

HY-111930

5-Iodo-indirubin-3'-monoxime	GSK-3 CDK	Cancer
5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC₅₀s of 9, 20 and 25 nM, respectively .

HY-112462

Cdk1/2 Inhibitor III	CDK	Cancer
Cdk1/2 Inhibitor III (compound 3n) is a highly potent and selective Cdk1/cyclin B and Cdk2/cyclin A inhibitor of with IC₅₀s of 0.6 nM and 0.5 nM, respectively. Cdk1/2 Inhibitor III shows selectivity over VEGF-R2 (IC₅₀ of 32 nM), GSK-3β (IC₅₀ of 140 nM), and a other kinases. Cdk1/2 Inhibitor III inhibits in cell proliferation with IC₅₀s of 20 nM, 35 nM and 92 nM for HCT-116, HeLa, and A375 cells, respectively .

HY-103383

(R)-DRF053 dihydrochloride	CDK Casein Kinase	Neurological Disease Cancer
(R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC₅₀s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .

HY-107419

NU6140 1 Publications Verification	CDK Aurora Kinase	Cancer
NU6140 is a selective CDK2-cyclin A inhibitor (IC₅₀, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC₅₀s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .

HY-N0417R

Cucurbitacin E (Standard) α-Elaterin (Standard); α-Elaterine (Standard)	Reference Standards CDK Autophagy	Cancer
Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0417

Cucurbitacin E Maximum Cited Publications 6 Publications Verification α-Elaterin; α-Elaterine	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Cancer	CDK Autophagy
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-N9561

Vanicoside B 1 Publications Verification	Structural Classification Polygonaceae Source classification Phenols Polyphenols Adiantum venustum Don Plants	CDK STAT
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis .

HY-N7045

Isosilybin B 2 Publications Verification	Structural Classification Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Flavanonols Flavonoids Glycine soya Phenols Polyphenols Disease Research Fields Cancer	Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce *cyclins* (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-N2424

Flavone 2-Phenyl-4-chromone	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	CDK Apoptosis Caspase
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21_waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21_waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .

HY-119833

Rubone	Structural Classification Chalcones Flavonoids Leguminosae Source classification Plants Brachypterum robustum (Roxburgh ex Candolle) Dalzell & Gibson	MicroRNA
Rubone, a chalcone analog, is a modulator of miR-34a. Rubone upregulates miR-34a expression in a p53 dependent manner, downregulates the downstream target Bcl-2 and Cyclin D1 expression, and suppresses hepatocellular carcinoma (HCC) growth in vivo. Rubone enhances the anticancer effect of Paclitaxel (PTX; HY-B0015) in PTX-resistant prostate cancer cell lines by reversing the expression of miR-34a downstream targets .

HY-N0417R

Cucurbitacin E (Standard) α-Elaterin (Standard); α-Elaterine (Standard)	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants	Reference Standards CDK Autophagy
Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-N7045R

Isosilybin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Reference Standards Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce *cyclins* (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

Cat. No.	Product Name	Chemical Structure

HY-15777S

Ribociclib-d6
Ribociclib-d₆ is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (hydrochloride) is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib . Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks